Metabolic syndrome in hemodialysis patients as a risk factor for new-onset diabetes mellitus after renal transplant: a prospective observational study

Josep Bonet1
Albert Martinez-Castelao2
Beatriz Bayés1

1Department of Nephrology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 2Department of Nephrology, Hospital Universitari de Bellvitge, IDIBELL, Hospital de Llobregat, Barcelona, Spain

Purpose: Metabolic syndrome is a cluster of biochemical abnormalities including cardiovascular and diabetes risk factors. The development of diabetes mellitus after renal transplant represents a major posttransplant complication that may adversely affect graft/patient survival. The aim of this study was to assess the role of metabolic syndrome in patients on hemodialysis as a risk factor for the incidence of new-onset diabetes mellitus after renal transplant.

Patients and methods: This was a prospective observational epidemiologic study carried out in adult nondiabetic patients undergoing chronic hemodialysis and on the renal transplant waiting list between November 2008 and April 2009. Patients were followed up from Visit 1 (baseline) to 6 months after the renal transplant. The analysis of the role of metabolic syndrome in hemodialysis patients as a risk factor for the incidence of new-onset diabetes mellitus after renal transplant included the estimation of relative risk and its 95% confidence interval (CI).

Results: A total of 383 evaluable patients were entered into the study (mean age, 52.7 years; male, 57.7%; Caucasian, 90.1%). The prevalence of metabolic syndrome on hemodialysis was 30.4% (95% CI, 25.8%–35.4%). Hypertension was the most prevalent criterion for metabolic syndrome (65.0%), followed by low levels of high-density lipoprotein cholesterol (52.7%), abdominal obesity (36.2%), hypertriglyceridemia (32.4%), and impaired glucose (8.9%). After the renal transplant, the prevalence of metabolic syndrome was still 25.8%. During the posttransplant period, the incidence of new-onset diabetes mellitus reached 13.0% (95% CI, 7.8%–20.6%) and patients with pretransplant metabolic syndrome were 2.6 times (95% CI, 1.043–6.608) more likely to develop new-onset diabetes mellitus after the renal transplant than those without metabolic syndrome.

Conclusion: The presence of metabolic syndrome in patients undergoing hemodialysis represents an independent risk factor for the incidence of new-onset diabetes mellitus after renal transplant.

Keywords: dialysis, kidney transplantation, metabolic syndrome X, posttransplant diabetes

Introduction
Metabolic syndrome is a cluster of biochemical and clinical abnormalities such as abdominal obesity, dyslipidemia, hypertension, and/or impaired blood glucose occurring simultaneously in a single individual. Even though the definition and pathogenesis of metabolic syndrome is still under debate, it is becoming a public health problem due to its effect on cardiovascular diseases. Indeed, metabolic syndrome increases the risk of cardiovascular diseases, even if it is just as a result of the combination of the cardiovascular risk factors defining metabolic syndrome. In addition, metabolic syndrome is closely associated with insulin resistance, a metabolic disorder characterized by impaired tissue responsiveness to the normal action of insulin that has been considered as one of the...
underlying causes of diabetes mellitus.\textsuperscript{8,9} In fact, metabolic syndrome has been suggested to be a predisease state beyond cardiovascular disease and diabetes, in which the infiltration of macrophages into adipose tissue characterized by an increased number of crown-like structures and inflammation are crucial for its metabolic consequences.\textsuperscript{2}

The development of new-onset diabetes after renal transplant (NODAT) represents a major posttransplant complication that may adversely affect graft/patient survival\textsuperscript{10–13} and increase the risk of cardiovascular events.\textsuperscript{13,14} Several factors have been identified as being related to the development of NODAT, some of which are potentially modifiable factors whose identification would help to develop strategies to improve outcomes. Among these potentially modifiable factors are cytomegalovirus/hepatitis C virus infection,\textsuperscript{11,15,16} early low-grade proteinuria,\textsuperscript{17} immunosuppressive therapy,\textsuperscript{10,11,16–18} arterial pressure/antihypertensive treatment,\textsuperscript{17,19} overweight/obesity,\textsuperscript{10,11,16,19,20} increased triglyceride levels,\textsuperscript{10,14,21} and higher blood glucose levels.\textsuperscript{14,18,22} Even though some of these factors also define metabolic syndrome, the specific role of metabolic syndrome in the development of diabetes has not been completely clarified yet. However, three recently published studies have shed some light on this matter, showing that diagnosis of metabolic syndrome after renal transplant\textsuperscript{23,24} and within the month prior to transplant\textsuperscript{25} was associated with an increased risk of NODAT.

In light of all the above, the aim of this study was to expand the information available about the relationship between metabolic syndrome and diabetes by assessing the role of metabolic syndrome in patients on hemodialysis as a risk factor for the incidence of NODAT.

### Material and methods

This study was conducted in accordance with the Guidelines for Ethical Review of Epidemiological Studies, the Declaration of Istanbul 2008, the World Medical Association 2000 Declaration of Helsinki, all its amendments, and national regulations. The study was approved by the ethics committee of Hospital Germans Trias i Pujol (Badalona, Spain) and all patients gave their written informed consent prior to their inclusion in the study.

### Patient population

This study included all patients meeting selection criteria that accepted to participate between November 2008 and April 2009. The main inclusion criteria comprised patients aged 18 years or older, undergoing chronic hemodialysis, without diabetes mellitus, and on the renal transplant waiting list. The main exclusion criteria were patients with any clinically relevant medical condition that, in the opinion of the investigator, made study participation unadvisable or those with a cognitive impairment precluding patients from giving their informed consent.

### Study design

This was a prospective observational epidemiologic study conducted at 22 Catalan dialysis centers (Spain).

The study follow-up comprised two different periods: pretransplant and posttransplant periods (Figure 1). The pretransplant period ranged from study Visit 1 (baseline) to renal transplant. The length of this period was variable, as it was not possible to foresee the time until renal transplant. Therefore, a maximum length of 30 months from baseline was established, based on the consideration that this time was sufficient (from the perspective of the authors’ previous experience in renal transplants carried out in Catalonia) to enable practically all patients to receive the renal transplant. During this period, a second and third visit at 12 months and 24 months were performed in those patients who had not received the renal transplant by these months. Thus, the

![Figure 1 Overall study design.](https://www.dovepress.com/)

number of study visits in the pretransplant period could range from one to three depending on the elapsed time between baseline and renal transplant. However, in the posttransplant period, only one study visit was performed 6 months after the renal transplant (final visit). Therefore, the maximum length of the study follow-up was 36 months.

All treatments were administered according to routine clinical practice and no restrictions regarding patients' treatment were specified in the study protocol.

Assessments

Data were collected by review of medical charts, physical examination, and information provided by patients during the study visits, according to routine clinical practice. Data collected at Visit 1 (baseline) included: demographics (age, gender, and ethnicity), anthropometrics (weight and height), family history of diabetes mellitus, renal function assessment and replacement treatment (hemodialysis start date), serology (hepatitis C virus, hepatitis B virus, and human immunodeficiency virus), concomitant treatments (antihypertensive drugs, lipid-lowering therapies, erythropoiesis-stimulating agents, phosphate binders, vitamin D, calcimimetics, and anticoagulant therapies), metabolic syndrome assessment based on the National Cholesterol Education Program Adult Treatment Panel III (ATP III) definition (waist circumference, blood pressure, high-density lipoprotein [HDL] cholesterol, triglycerides, and fasting blood glucose), concomitant cardiovascular diseases/cerebrovascular events, and cardiovascular risk factors (lack of regular exercise, snoring, smoking habit, and alcohol consumption).

When Visit 2 (12 months) and Visit 3 (24 months) were performed, the data collected included serology, concomitant treatments, metabolic syndrome assessment according to ATP III criteria, concomitant cardiovascular diseases/cerebrovascular events, and cardiovascular risk factors.

Six months after renal transplant, data on renal transplant (date of transplant, donor, immunosuppressive therapy, and graft rejection), metabolic syndrome assessment according to ATP III criteria, and NODAT were also collected. The diagnosis of metabolic syndrome was made – according to ATP III criteria – when three or more of the following risk determinants were present: abdominal obesity (waist circumference >102 cm in men or >88 cm in women), hypertriglyceridemia (triglycerides \( \geq 150 \) mg/dL), low levels of HDL cholesterol (<40 mg/dL in men or <50 mg/dL in women), hypertension (blood pressure \( \geq 130 \) mmHg/\( \geq 85 \) mmHg), and impaired glucose (fasting blood glucose \( \geq 110 \) mg/dL).\(^1\)

Diabetes mellitus was diagnosed based on the American Diabetes Association criteria, either when symptoms of diabetes plus casual blood glucose concentration \( \geq 200 \) mg/dL were present or when fasting blood glucose was \( \geq 126 \) mg/dL or when the 2-hour postload glucose was \( \geq 200 \) mg/dL during the oral glucose tolerance test.\(^{26}\)

Statistical considerations

The primary efficacy endpoint was the presence of metabolic syndrome in patients on hemodialysis as a risk factor for the incidence of NODAT. Analysis of this primary endpoint included the estimation of relative risk and its 95% confidence interval (CI).

The secondary endpoints were the most prevalent criteria for metabolic syndrome in patients undergoing hemodialysis on the waiting list for renal transplant, the prevalence of metabolic syndrome without diabetes mellitus in this patient population, the concomitant cardiovascular diseases/cerebrovascular events and cardiovascular risk factors before renal transplant, and the incidence of NODAT. Analysis of these secondary endpoints was performed using descriptive methods (frequencies and valid percentages for categorical variables, and measures of central tendency and dispersion for quantitative variables). In addition, 95% CI for the prevalence of metabolic syndrome without diabetes mellitus in patients undergoing hemodialysis on the waiting list for renal transplant and for incidence of NODAT were also calculated.

Missing data were not considered in the analyses, which were performed with SPSS Statistics version 17.0 (SPSS Inc, Chicago, IL, USA).

Results

Patient characteristics

A total of 418 patients were screened from a total Catalanian population of 7.5 million inhabitants (990 new patients in substitutive renal therapy and 471 renal transplants in 2008; and 1,064 new patients in substitutive renal therapy and 524 renal transplants in 2009), representing, at that time, 49.5% of all nondiabetic patients on the renal transplant waiting list in Catalonia (Spain). Two of the screened patients were screening failures and 33 were nonevaluable as a result of insufficient data available for the study. Thus, the evaluable population comprised a total of 383 patients (Figure 2). Baseline characteristics of evaluable patients are described in Table 1.

Pretransplant period

Patients remained on hemodialysis an average (standard deviation [SD]) of 4.8 (4.5) years before receiving a renal transplant.

Statistical considerations

The primary efficacy endpoint was the presence of metabolic syndrome in patients on hemodialysis as a risk factor for the incidence of NODAT. Analysis of this primary endpoint included the estimation of relative risk and its 95% confidence interval (CI).

The secondary endpoints were the most prevalent criteria for metabolic syndrome in patients undergoing hemodialysis on the waiting list for renal transplant, the prevalence of metabolic syndrome without diabetes mellitus in this patient population, the concomitant cardiovascular diseases/cerebrovascular events and cardiovascular risk factors before renal transplant, and the incidence of NODAT. Analysis of these secondary endpoints was performed using descriptive methods (frequencies and valid percentages for categorical variables, and measures of central tendency and dispersion for quantitative variables). In addition, 95% CI for the prevalence of metabolic syndrome without diabetes mellitus in patients undergoing hemodialysis on the waiting list for renal transplant and for incidence of NODAT were also calculated.

Missing data were not considered in the analyses, which were performed with SPSS Statistics version 17.0 (SPSS Inc, Chicago, IL, USA).

Results

Patient characteristics

A total of 418 patients were screened from a total Catalanian population of 7.5 million inhabitants (990 new patients in substitutive renal therapy and 471 renal transplants in 2008; and 1,064 new patients in substitutive renal therapy and 524 renal transplants in 2009), representing, at that time, 49.5% of all nondiabetic patients on the renal transplant waiting list in Catalonia (Spain). Two of the screened patients were screening failures and 33 were nonevaluable as a result of insufficient data available for the study. Thus, the evaluable population comprised a total of 383 patients (Figure 2). Baseline characteristics of evaluable patients are described in Table 1.

Pretransplant period

Patients remained on hemodialysis an average (standard deviation [SD]) of 4.8 (4.5) years before receiving a renal transplant.
Serology tests conducted before renal transplant showed that 41 (10.8%) patients tested positive for hepatitis C virus, three (0.8%) patients tested positive for hepatitis B virus, and two (0.5%) patients for human immunodeficiency virus.

In the last pretransplant visit, 206 (55.5%) patients were receiving antihypertensive treatment (calcium channel blockers, n = 103; beta-blockers, n = 89; alpha-blockers, n = 53; angiotensin II receptor antagonists, n = 52; angiotensin-converting enzyme inhibitors, n = 51; loop of Henle diuretics, n = 21; others, n = 23), and 164 (44.1%) patients were receiving lipid-lowering treatment (statins, n = 141; fibrates, n = 19; ezetimibe, n = 4; others, n = 8). Other concomitant treatments included erythropoiesis-stimulating agents (307 [82.5%] patients), phosphate binders (337 [90.8%] patients), vitamin D (197 [53.2%] patients), calcimimetics (170 [44.4%] patients), and anticoagulant therapy (91 [24.5%] patients).

The assessment of metabolic syndrome criteria showed that hypertension was the most prevalent criterion (234 [65.0%] patients), followed by low levels of HDL cholesterol (187 [52.7%] patients), abdominal obesity (118 [36.2%] patients), hypertriglyceridemia (118 [32.4%] patients), and impaired glucose (32 [8.9%] patients). In addition, the prevalence of metabolic syndrome without diabetes mellitus in this patient population was 30.4% (95% CI, 25.8%–35.4%). The characteristics of patients with pretransplant metabolic syndrome are described in Table 2.

During this period, 107 (28.8%) patients reported having had at least one cardiovascular disease (peripheral arteriopathy, n = 49; carotid artery atherosclerosis, n = 34; angina pectoris, n = 33; heart attack, n = 16; congestive heart failure, n = 14; coronary revascularization, n = 10; deep venous thromboembolism, n = 7; pulmonary thromboembolism, n = 3). Additionally, 28 (7.3%) patients...
reported having experienced some cerebrovascular event (ischemic stroke, n = 11; hemorrhagic stroke, n = 10; transient ischemic attack, n = 9). In the last pretransplant visit, the main cardiovascular risk factor was the lack of regular exercise (213 [58.7%] patients), followed by snoring (121 [34.0%] patients), smoking habit (64 [17.4%] patients), and alcohol consumption (8 [2.2%] patients).

Renal transplant

A renal transplant was finally performed in 138 (36.0%) patients after an average (SD) of 11.9 (8.9) months from baseline. In 119 (86.9%) patients, renal transplants were received from a deceased donor and 17 (12.6%) were relative donors. The immunosuppressive treatment was mainly based on a triple therapy composed of calcineurin inhibitors or mammalian target of rapamycin inhibitors, mycophenolate mofetil/mycophenolic acid, and prednisone (93 [76.9%] patients). Calcineurin inhibitors were administered in 100 (84.0%) patients (tacrolimus, n = 98; cyclosporine, n = 2), mammalian target of rapamycin inhibitors in 18 (15.1%) patients (everolimus, n = 11; sirolimus, n = 7), mycophenolate mofetil in 42 (35.3%) patients, mycophenolic acid in 64 (53.8%) patients, and prednisone in 113 (92.6%) patients. The latter patients received 250 mg of prednisone at renal transplant, 125 mg on the first day after transplant, and 20 mg from the second to the 15th day after transplant. From the 16th day after transplant, patients received 15 mg of prednisone and, after 2 months, prednisone was decreased to a maintenance dose of 5 mg/day. Graft rejection was reported in six (4.7%) patients (acute rejection, n = 5; chronic rejection, n = 1), three of whom received methylprednisolone bolus of 500 mg/day for 3 days as transplant rejection treatment.

Posttransplant period

After the renal transplant, patients had a mean (SD) waist circumference of 93.8 (12.4) cm, mean (SD) systolic blood pressure of 135.1 (19.1) mmHg, mean (SD) diastolic blood pressure of 75.8 (10.8) mmHg, mean (SD) HDL cholesterol levels of 53.1 (16.3) mg/dL, mean (SD) triglyceride levels of 151.0 (83.8) mg/dL, and mean (SD) fasting blood glucose levels of 96.4 (18.4) mg/dL. Additionally, a total of 24 (25.8%) patients met the criteria for metabolic syndrome. The characteristics of patients with metabolic syndrome after renal transplant are described in Table 2. The prevalence of metabolic syndrome during the follow-up did not significantly increase in patients not receiving a renal transplant in comparison to patients receiving the transplant (P = 0.124). In addition, the duration of hemodialysis did not significantly affect the occurrence of metabolic syndrome after the renal transplant (P = 0.425).

The incidence of NODAT was 13.0% (95% CI, 7.8%–20.6%). Among patients receiving a renal transplant, the relative risk of developing NODAT in hemodialysis patients with metabolic syndrome was estimated to be 2.625 (95% CI, 1.043–6.608). Therefore, patients with metabolic syndrome in hemodialysis patients a risk factor for NODAT

Table 1 Baseline patient characteristics (N = 383)

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years (SD)</td>
<td>52.7 (12.3)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>221 (57.7)</td>
</tr>
<tr>
<td>Ethnicity, n (%)</td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>345 (90.1)</td>
</tr>
<tr>
<td>Other</td>
<td>38 (9.9)</td>
</tr>
<tr>
<td>Mean weight, kg (SD)</td>
<td>67.6 (13.1)</td>
</tr>
<tr>
<td>Mean height, cm (SD)</td>
<td>164.3 (9.5)</td>
</tr>
<tr>
<td>Body mass index</td>
<td></td>
</tr>
<tr>
<td>Mean body mass index, kg/m² (SD)</td>
<td>25.0 (4.4)</td>
</tr>
<tr>
<td>Mean body mass index ≥30 kg/m², n (%)</td>
<td>44 (11.8)</td>
</tr>
<tr>
<td>Family history of diabetes mellitus, n (%)</td>
<td>81 (22.3)</td>
</tr>
<tr>
<td>Main CKD etiology, n (%)</td>
<td></td>
</tr>
<tr>
<td>Glomerulonephritis</td>
<td>100 (26.2)</td>
</tr>
<tr>
<td>Unknown</td>
<td>98 (25.7)</td>
</tr>
<tr>
<td>Polycystic disease</td>
<td>57 (15.0)</td>
</tr>
<tr>
<td>Vascular disease</td>
<td>35 (9.2)</td>
</tr>
<tr>
<td>Mean waist circumference, cm (SD)</td>
<td>92.9 (13.2)</td>
</tr>
<tr>
<td>Mean systolic blood pressure, mmHg (SD)</td>
<td>134.9 (20.9)</td>
</tr>
<tr>
<td>Mean diastolic blood pressure, mmHg (SD)</td>
<td>77.3 (12.7)</td>
</tr>
<tr>
<td>Mean HDL cholesterol levels, mg/dL (SD)</td>
<td>45.1 (13.8)</td>
</tr>
<tr>
<td>Triglyceride levels, mg/dL (SD)</td>
<td>144.6 (82.2)</td>
</tr>
<tr>
<td>Fasting blood glucose levels, mg/dL (SD)</td>
<td>85.3 (14.3)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CKD, chronic kidney disease; HDL, high-density lipoprotein; SD, standard deviation.

Table 2 Characteristics of patients with metabolic syndrome before and after renal transplant

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Pretransplant metabolic syndrome (N = 112)</th>
<th>Posttransplant metabolic syndrome (N = 24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean waist circumference, cm (SD)</td>
<td>100.4 (13.1)</td>
<td>97.0 (12.6)</td>
</tr>
<tr>
<td>Mean systolic blood pressure, mmHg (SD)</td>
<td>141.8 (19.7)</td>
<td>138.1 (17.0)</td>
</tr>
<tr>
<td>Mean diastolic blood pressure, mmHg (SD)</td>
<td>78.9 (12.9)</td>
<td>76.7 (10.2)</td>
</tr>
<tr>
<td>Mean HDL cholesterol levels, mg/dL (SD)</td>
<td>37.2 (7.6)</td>
<td>45.2 (11.3)</td>
</tr>
<tr>
<td>Mean triglyceride levels, mg/dL (SD)</td>
<td>189.9 (89.1)</td>
<td>225.5 (100.8)</td>
</tr>
<tr>
<td>Fasting blood glucose levels, mg/dL (SD)</td>
<td>94.5 (24.8)</td>
<td>110.5 (26.8)</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>0 (0.0)</td>
<td>7 (29.2)</td>
</tr>
</tbody>
</table>

**Abbreviations:** HDL, high-density lipoprotein; SD, standard deviation.
Discussion
This study showed that NODAT may affect 13.0% of patients receiving a renal transplant, among whom the presence of metabolic syndrome undergoing hemodialysis represents a risk factor that increases the likelihood of developing NODAT by 2.6 times. Recently published studies carried out in renal transplant recipients reported NODAT as a common condition, with incidences ranging from 13.0%–46.3% over 5 years posttransplant. These studies also supported the association between the presence of metabolic syndrome prior to transplantation in order to establish therapeutic interventions to correct metabolic syndrome defining risk factors. In the current study, the main criterion for metabolic syndrome in patients on hemodialysis was hypertension, followed by low levels of HDL cholesterol, abdominal obesity, hypertriglyceridemia, and impaired glucose, and almost one-third of patients met the criteria for metabolic syndrome. Even though the information reported by previous studies carried out in patients on hemodialysis is limited and no data is available in the specific population of nondiabetic patients, the prevalence of metabolic syndrome during hemodialysis has been shown to range from 28.7%–61.0%. However, the differences in the criteria used to diagnose metabolic syndrome makes their comparison difficult.

Hypertension has been described as one of the most important factors for the development of metabolic syndrome, together with central obesity. However, the criteria for central obesity also differed among the various studies, some of which measured it according to waist circumference while others used the body mass index. In the current study, even though central obesity measured as waist circumference was the third most frequent metabolic syndrome defining risk factor in patients on hemodialysis, obesity measurement according to the body mass index only accounted for 11.8% of patients. The magnitude of influence of other metabolic syndrome defining risk factors in patients on hemodialysis has not yet been fully clarified, as variable information has been reported by the different studies carried out depending on the criteria used for the diagnosis of metabolic syndrome.

After renal transplant, the current study also showed the presence of metabolic syndrome in 25.8%, which did not significantly differ from patients not receiving a renal transplant. Renal transplant recipients with metabolic syndrome and/or NODAT have been shown to display a worse metabolic and cardiovascular profile despite the higher prevalence in the use of statins and antihypertensive medications. In the current patient population, one-half of patients were receiving antihypertensive treatment and approximately one-third were under treatment with statins in the last pretransplant visit. These results differ from those previously reported within the month prior to transplant, showing percentages of 83% and 17% for antihypertensive and statin treatments, respectively. The difference in results may represent the variability of patient populations, mainly in terms of blood pressure and lipid control, and health system differences in the care of renal transplant recipients. Since they constitute important risk factors for cardiovascular events, and metabolic syndrome has been shown to be a risk enhancer for cardiovascular diseases, increased emphasis on controlling metabolic syndrome defining factors has been recommended. In the current study, more than one-quarter of patients reported having had at least one cardiovascular disease and approximately 7% having experienced some cerebrovascular event during the hemodialysis period, but no information was collected during the posttransplant period. Therefore, the lack of information on cardiovascular events after the renal transplant and the short follow-up during the study period precluded the establishing of conclusions.

The authors recognize that other limitations apart from the previously mentioned absence of collection of information on posttransplant cardiovascular events must be considered when interpreting these results. That is the case for the decreased number of patients with data available for the 6-month analyses after the renal transplant. Thus, although the study was designed as prospective to obtain stronger evidence, this reduced data available after transplant might have affected it. The authors also recognize that it would have been better to measure insulin resistance by homeostatic model of assessment — insulin resistance but, unfortunately, homeostatic model of assessment values were only available in a small percentage of patients. In addition, even though this study aimed to include all patients meeting selection criteria during the recruitment period, potential selection biases cannot be ruled out. However, the multicenter nature of the study and the predominant selection of objective secondary endpoints aimed at minimizing potential biases. In fact, the authors consider that the results obtained in the
study are representative of renal recipients from their geographical area. However, it cannot be asserted that they were representative of renal recipients from other geographical areas with different ethnic composition.

**Conclusion**

In conclusion, this study shows that patients with metabolic syndrome on hemodialysis were 2.6 times more likely to develop NODAT than those without metabolic syndrome. In this patient population on hemodialysis, the main metabolic syndrome risk factor was hypertension, followed by low levels of HDL cholesterol, abdominal obesity, hypertriglyceridemia, and impaired glucose. The impact of metabolic syndrome on cardiovascular events and diabetes onset reinforces the need to control metabolic syndrome risk factors. Further clinical trials confirming the role of metabolic syndrome as a predictor of NODAT and assessing the benefit of interventions targeting metabolic syndrome risk factors still need to be conducted.

**Acknowledgments**

This work was sponsored by Fundació Catalana de Nefrología and funded by Boehringer Ingelheim. This work was done on behalf of the SIMEDIT Study Group. All investigators of the SIMEDIT Study Group participating in the study data collection are: Josep Bonet (Hospital Universitari Germans Trias i Pujol, Badalona, Spain), Albert Martínez-Castelao (Hospital Universitari de Bellvitge, IDIBELL, Hospital de Llobregat, Spain), Beatriz Bayés (Hospital Universitari Germans Trias i Pujol, Badalona, Spain), Miguel Hueso-Val (Institut Nefrologc Hospital de Llobregat), Joan Manuel Díaz-Gómez (Fundació Puigvert, Barcelona, Spain), Josep Maria Brongsom-Artero (Clínica Girona, Girona, Spain), Maria Isabel Troya-Saborido (Hospital Germans Trias i Pujol, Badalona, Spain), Jordi Soler-García (Kidney Centers Holding SL, Reus, Spain), Maria del Pilar Fernández-Crespo (Institut Mèdic Badalona SL, Badalona, Spain), Francisco Maduell-Canals (Hospital Clínico Barcelona, Barcelona, Spain), Nuria Garra-Moncau (Althaia, Manresa, Spain), Montserrat Belart-Rodriguez (Sistemes Renals SA, Lleida, Spain), Mercè Homs-del-Valle (Consortit Hospitalari de Vic, Vic, Spain), Antoni Pelegri-Santos (Centro de Dialisis Verge de Montserrat, Barcelona, Spain), Vicent Esteve-Simó (Hospital Terrassa, Terrassa, Spain), Gloria Martín-Martínez (Instituto de Hemodiálisis Barcelona, Barcelona, Spain), Silvia Collado-Nieto (Hospital del Mar, Barcelona, Spain), Rosa Ramos-Sánchez (Hospital Comarcal de Sant Antoni Abat, Vilanova i la Geltrú, Spain), Joan Fort-Ros (Hospital de la Vall d'Hebron, Barcelona, Spain), Felip Sarró-Sobrin (Hospital Arnau de Vilanova, Lleida, Spain), Silvia Peña-Cadierno (Hospital d’Igualada, Igualada, Spain), Carmen Puig-Mari (Hospital d’Igualada, Igualada, Spain), Josep Riba-Pola (Hospital d’Igualada, Igualada, Spain), Mercedes Arruche-Herrero (Pius Hospital de Valls, Valls, Spain), Isabel Naval-Marcos (Althaia, Manresa, Spain), Concepción Buñons-Noguera (Hospital d’Igualada, Igualada, Spain), Montserrat Vallvé-Alvarez (Hospital Joan XXIII, Tarragona, Spain), Martí Vallés-Prats (Hospital de Girona Josep Trueta, Girona, Spain), and Francesc Barbosa-Puig (Hospital del Mar, Barcelona, Spain). Medical writing support was provided by Esther Álvarez-García and Antonio Torres-Ruiz at Dynamic SL during the preparation of this paper, funded by Fundació Catalana de Nefrología.

**Disclosure**

The authors of this manuscript declare that Josep Bonet has participated in clinical trials and has given speeches sponsored by Boehringer Ingelheim. Albert Martínez-Castelao has received honoraria for conferences sponsored by Abbott, Amgen, Boehringer Ingelheim, Novartis, Roche, and Shire; and has acted as consultant and board member for Abbott, Amgen, Boehringer Ingelheim, and Roche. Beatriz Bayés has no conflicts of interest in relation to this manuscript, though she has been sponsored by Novartis, Roche, Stellas, and Boehringer Ingelheim. Responsibility for opinions, conclusions, and interpretation of data lies with the authors.

**References**